Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Lexicon Pharmaceuticals (LXRX) Receivables - Net (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Receivables - Net for 6 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net fell 31.36% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 31.36% decrease, with the full-year FY2025 number at $2.4 million, down 31.36% from a year prior.
  • Receivables - Net was $2.4 million for Q4 2025 at Lexicon Pharmaceuticals, up from $2.3 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $47.4 million in Q1 2025 to a low of $261000.0 in Q1 2023.
  • A 3-year average of $5.6 million and a median of $2.3 million in 2025 define the central range for Receivables - Net.
  • Biggest YoY gain for Receivables - Net was 3009.24% in 2025; the steepest drop was 31.36% in 2025.
  • Lexicon Pharmaceuticals' Receivables - Net stood at $1.0 million in 2023, then soared by 243.86% to $3.5 million in 2024, then plummeted by 31.36% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Receivables - Net are $2.4 million (Q4 2025), $2.3 million (Q3 2025), and $2.2 million (Q2 2025).